Regeneron

Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Market Realist
Sanofi
Kevzara
rheumatoid arthritis
Regeneron
Flag link:
Regeneron-Sanofi food allergy drug succeeds mid-stage study
Regeneron-Sanofi food allergy drug succeeds mid-stage study
Yahoo/Reuters
Regeneron
Amgen
food allergies
eosinophilic esophagitis
Dupixent
Flag link:
PCSK9 court saga drags on for Sanofi, Regeneron and Amgen
PCSK9 court saga drags on for Sanofi, Regeneron and Amgen
Biopharma Dive
Sanofi
Regeneron
Amgen
PCSK9 inhibitors
Praluent
Repatha
Flag link:
U.S. court reverses ban on sale of Sanofi, Regeneron drug Praluent
U.S. court reverses ban on sale of Sanofi, Regeneron drug Praluent
Yahoo/Reuters
Sanofi
Regeneron
Praluent
Repatha
patents
Flag link:
Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen
Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen
Fierce Pharma
Sanofi
Regeneron
Dupixent
IPR
Amgen
patents
Flag link:
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Fierce Pharma
Sanofi
Amgen
PCSK9 inhibitors
diabetes
Regeneron
Praluent
Repatha
Flag link:
5 Things Regeneron's CEO Said as the Biotech Stock Sank
5 Things Regeneron's CEO Said as the Biotech Stock Sank
Motley Fool
Regeneron
Pharma CEOs
Leonard Schleifer
Sanofi
Dupixent
Flag link:
Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing
Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing
Xconomy
Regeneron
asthma
FDA
Sanofi
Dupixent
Flag link:
AbbVie preps JAK atopic dermatitis candidate for phase 3
AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
AbbVie
JAK inhibitors
clinical trials
atopic dermatitis
Upadacitinib
Sanofi
Regeneron
Dupixent
Flag link:
Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance
Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance
Endpoints
Sanofi
Regeneron
fast track
breakthrough status
cemiplimab
anti-PD-L1
Flag link:
Insurers, doctors battle over new heart disease drugs
Insurers, doctors battle over new heart disease drugs
CNBC
insurers
cardiovascular disease
statins
PCSK9 inhibitors
Amgen
Regeneron
Sanofi
Repatha
Praluent
Flag link:
3 Strong Biotech Stocks In 2017
3 Strong Biotech Stocks In 2017
Forbes
Regeneron
Calithera Biosciences
Dynavax Technologies
Flag link:
In cost debate, Amgen stands by Repatha's value
In cost debate, Amgen stands by Repatha's value
BioPharma Dive
Amgen
Repatha
drug pricing
PCSK9 inhibitors
Praluent
Sanofi
Regeneron
Flag link:
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Fierce Pharma
Pfizer
Eucrisa
DTC
eczema
Dupixent
Sanofi
Regeneron
Flag link:
In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure
In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure
Endpoints
Regeneron
RSV
clinical trials
REGN2222
suptavumab
Flag link:
Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance
Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance
Endpoints
Sanofi
R&D
Regeneron
drug development
Flag link:
Regeneron Earnings, Revenue Top Views; Shares Down Slightly
Regeneron Earnings, Revenue Top Views; Shares Down Slightly
Investors Business Daily
Regeneron
earnings
Flag link:
Earnings Preview: What To Expect From Regeneron Pharmaceuticals on Thursday
Earnings Preview: What To Expect From Regeneron Pharmaceuticals on Thursday
Forbes
Regeneron
earnings
Flag link:
Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent
Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent
Fierce Pharma
payers
Sanofi
Regeneron
eczema
Dupixent
dupilumab
Flag link:
The top 15 highest-paid biopharma executives
The top 15 highest-paid biopharma executives
Fierce Pharma
executive pay
Mylan Labs
Valeant Pharmaceuticals
Medivation
Regeneron
JNJ
Merck
Flag link: